Hansa Biopharma sees 2025 growth through expanded IDEFIRIX adoption and new market ...
Q4 2024 Management View CEO Soren Tulstrup highlighted full-year 2024 revenue of SEK 171.3 million, marking a 28% year-over-year increase, with IDEFIRIX product sales contributing SEK 140.1 million ...